Bronchiectasis Pipeline Summary

DelveInsight’s, “Bronchiectasis - Pipeline Insight, 2026” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Bronchiectasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Bronchiectasis: Understanding

Bronchiectasis: Overview

Bronchiectasis was first described in the early 19th century by René Laennec. It is a chronic and progressive respiratory condition characterized by permanent widening and structural damage of the bronchial airways, accompanied by impaired mucociliary clearance. Recurrent infections and persistent airway inflammation can weaken the normal mechanisms responsible for removing mucus and pathogens from the lungs, resulting in mucus accumulation and pooling throughout the bronchial tree. This stagnant mucus creates a favorable environment for bacterial colonization and repeated respiratory infections, which can further exacerbate airway damage and disease progression. Over time, bronchiectasis can lead to a substantial and irreversible decline in lung function, with recurrent exacerbations significantly affecting patients' quality of life. In severe cases, the disease may result in considerable morbidity, respiratory complications, and increased risk of premature mortality.

Historically, respiratory infections, particularly during childhood, were considered a major cause of bronchiectasis; however, the disease has a broad and multifactorial etiology and may be idiopathic, acquired, or infection-related. Infectious causes include bacterial pathogens such as Mycobacterium, Haemophilus influenzae, Pseudomonas aeruginosa, Staphylococcus aureus, and Mycoplasma, along with viral and fungal infections. Other causes include bronchial obstruction from foreign bodies, mucus plugs, tumors, or hilar lymphadenopathy; chronic aspiration, gastroesophageal reflux, sinusitis, and inhalational injury; and genetic or congenital disorders such as cystic fibrosis, primary ciliary dyskinesia, immunodeficiency, alpha-1 antitrypsin deficiency, and Mounier-Kuhn syndrome. Bronchiectasis is also associated with inflammatory and autoimmune diseases including ulcerative colitis, rheumatoid arthritis, and Sjögren syndrome, as well as pulmonary conditions such as asthma, bronchomalacia, COPD, diffuse panbronchiolitis, and idiopathic pulmonary fibrosis. Additional contributors include allergic bronchopulmonary aspergillosis, hypersensitivity pneumonitis, and rare disorders such as Yellow Nail Syndrome.

The pathogenesis of bronchiectasis is primarily driven by recurrent infections, airway obstruction, and peribronchial fibrosis, which collectively promote persistent airway inflammation and structural damage. Neutrophils are the predominant inflammatory cells, attracted by elevated levels of chemoattractants such as interleukin-8 (CXCL8) and leukotriene B4. Impaired mucociliary clearance, together with defective neutrophil-mediated bacterial killing, facilitates persistent bacterial colonization and recurrent infections. Additional immune dysfunction, including impaired clearance of apoptotic cells and increased T-cell infiltration, particularly Th17-cell activity, further sustains airway inflammation. These processes ultimately result in cartilage destruction, fibrosis, mucosal and mucus-gland hyperplasia, inflammatory cell infiltration, and excessive mucus and airway exudate, leading to progressive and irreversible airway damage.

Evaluation of bronchiectasis involves identifying the underlying cause, confirming airway damage, and assessing disease severity. Investigations may include immunoglobulin levels, ABPA testing, sputum cultures for bacterial and nontuberculous mycobacterial infections, autoantibodies, and, when indicated, testing for cystic fibrosis, alpha-1 antitrypsin deficiency, ciliary dysfunction, and HIV. Chest X-ray is typically the initial imaging test, while thin-section chest CT is preferred for definitive diagnosis and characterization, showing bronchial dilation, lack of tapering, and patterns such as cylindrical, varicose, or cystic bronchiectasis. CT may also reveal mucus plugging, air trapping, lobar collapse, dilated bronchial arteries, or mycetoma. Pulmonary function testing commonly demonstrates airflow obstruction with reduced FEV1 and increased residual volume due to air trapping.

Bronchiectasis is treatable but rarely curable, with management aimed at treating the underlying cause, improving mucus clearance, controlling infections, and managing airflow obstruction. Cause-specific treatment may include immunoglobulin replacement, corticosteroids, antifungals for ABPA, treatment of nontuberculous mycobacterial infection, and cystic fibrosis therapies. Airway clearance through postural drainage, breathing exercises, chest physiotherapy, and mechanical devices is a key component of care. Antibiotics, selected according to sputum culture and disease severity, are used to manage exacerbations, while long-term or inhaled antibiotics may be considered for selected patients with chronic bacterial colonization. Bronchodilators and inhaled corticosteroids may be used when airflow obstruction is present. Smoking cessation and influenza and pneumococcal vaccination are also recommended. Surgery is reserved for selected cases with localized or advanced disease or severe complications such as massive hemoptysis, while lung transplantation may be considered for end-stage disease, particularly in cystic fibrosis.

"Bronchiectasis- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bronchiectasis pipeline landscape is provided which includes the disease overview and Bronchiectasis treatment guidelines. The assessment part of the report embraces, in depth Bronchiectasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bronchiectasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Bronchiectasis R&D. The therapies under development are focused on novel approaches to treat/improve Bronchiectasis.

Bronchiectasis Emerging Drugs Chapters

This segment of the Bronchiectasis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bronchiectasis Emerging Drugs

BI1291583: Boehringer Ingelheim

BI1291583 (verducatib) is an investigational oral, reversible, selective cathepsin C (CatC)/dipeptidyl peptidase 1 (DPP1) inhibitor being developed by Boehringer Ingelheim for bronchiectasis. By inhibiting CatC, which activates neutrophil serine proteases such as neutrophil elastase, the therapy aims to reduce neutrophil-driven inflammation, airway damage, and pulmonary exacerbations. According to company’s pipeline the drug is in Phase III stage of it’s development for the treatment of Bronchiectasis.

GSK3862995B: GSK

GSK3862995B is an investigational anti-interleukin-33 (IL-33) monoclonal antibody being developed by GSK for the treatment of bronchiectasis. By blocking IL-33, a key mediator of airway inflammation and immune activation, GSK3862995B is designed to reduce airway inflammation and pulmonary exacerbations. The therapy is currently being evaluated in a Phase II study in adults with bronchiectasis, assessing its efficacy, safety, pharmacokinetics, and immunogenicity, with the annualized rate of pulmonary exacerbations as a key efficacy endpoint.

CHF6333: Chiesi Farmaceutici

CHF6333 is an investigational, inhaled human neutrophil elastase (HNE) inhibitor being developed by Chiesi for bronchiectasis. By directly inhibiting HNE, a key enzyme involved in neutrophil-driven airway inflammation and tissue damage, CHF6333 is intended to reduce airway inflammation and potentially disease progression and exacerbations. The drug is administered via a dry-powder inhaler and has previously been evaluated in patients with –cystic fibrosis and non-CF bronchiectasis. According to company’s pipeline, the therapy is in Phase II stage of its’s development for the treatment of Bronchiectasis.

CTX-187: Centauri Therapeutics

Centauri’s lead clinical candidate, CTX-187, is a novel antimicrobial being developed to address clinically prevalent and multidrug-resistant Gram-negative bacterial infections. In March 2026, CTX-187 received Qualified Infectious Disease Product (QIDP) designation from the FDA, making it eligible for benefits including potential Fast Track designation and Priority Review. The candidate employs a dual mechanism of action, combining direct antibacterial activity with an immunotherapeutic approach that promotes anti-glycan antibody recruitment, complement activation, and opsonophagocytosis to enhance bacterial clearance. Currently, the therapy is in Phase I stage of its development for the treatment of Bronchiectasis.

Further product details are provided in the report……..

Bronchiectasis: Therapeutic Assessment

This segment of the report provides insights about the different Bronchiectasis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Bronchiectasis
• There are approx. 15+ key companies which are developing the therapies for Bronchiectasis. The companies which have their Bronchiectasis drug candidates in the most advanced stage, i.e. Phase III include, Boehringer Ingelheim.

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bronchiectasis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Bronchiectasis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bronchiectasis drugs.

Bronchiectasis Report Insights

• Bronchiectasis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Bronchiectasis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Bronchiectasis drugs?
• How many Bronchiectasis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bronchiectasis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bronchiectasis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Bronchiectasis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Boehringer Ingelheim
• GSK
• Chiesi Farmaceutici S.p.A.
• Hasico Pharmaceuticals
• Centauri Therapeutics
• VAST Therapeutics
• Fosun Pharma / Expedition Therapeutics
• UCB
• CSL Behring
• Thirty Respiratory Limited
• AstraZeneca
• Roche

Key Products

• BI 1291583
• GSK3862995B
• CHF10196
• CHF6333
• CTX-187
• ALX1
• FXS7553
• Galvokimig
• CSL787
• RESP302
• AZD0292
• GDC-6988